Takeda Italia, 10 years of commitment against cancer

CopyAMP code

The Oncology Division of the Japanese pharma has been present in our country for ten years. A decade characterized by a solid pipeline and collaboration with the scientific community and patients to contribute to research projects, improve access, management and information.


Takeda Italia, on the eve of the Lymphoma Awareness Day, which is celebrated on September 15 all over the world, reaffirms its commitment in the area of ​​oncology and oncohematology, on the occasion of the tenth anniversary of the establishment of the Division of Oncology in our Village. A presence, that of Takeda in Oncology, already active before 2012, but which with the birth of a dedicated Division has been consolidated day by day and which today sees the Company alongside operators and institutions to ensure cancer patients the best treatment path, making the most innovative therapeutic solutions available quickly and working to ensure equity in access to the most appropriate treatments.

In this decade Takeda has confirmed its commitment, starting precisely with oncohematology: since 2012, in fact, brentuximab vedotin, a monoclonal anti-CD30 antibody conjugated to a drug, has been available in Italy for the treatment of adult patients with CD30 + Hodgkin’s lymphoma. relapsed or refractory and for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma. A drug that has changed not only clinical practice, but above all the natural history of a haematological neoplasm such as Hodgkin’s lymphoma, which affects young adults, restoring their prospects of survival.

In 2020, the Japanese pharma enters the lung cancer area, making brigatinib, a new generation tyrosine kinase inhibitor, indicated in the first-line treatment of ALK non-small cell lung cancer, available to patients. positive.

“Meeting the unique needs of patients is what drives Research and our daily work with the cancer community – he says Anna Maria Bencini, Oncology Country Head, Takeda Italy – our primary commitment is to innovative therapies capable of transforming people’s lives, seeking to unlock the potential of innovation. But there is more. We want to help cure cancer by going beyond therapy, with initiatives that support patients and caregivers through a wide-ranging approach: not only the disease, but also the socio-assistance and organizational context, their experience and their psyche “.

Takeda now offers patients treatments for oncological diseases, such as lung, prostate, breast and Hodgkin’s lymphoma, and for rare cancers, such as multiple myeloma, osteosarcoma and systemic anaplastic large cell lymphoma. A commitment in oncology also guided by investments in research that focus on those patients for whom there are few or inadequate therapeutic treatments.

“There is a lot of turmoil globally, where Takeda’s clinical research focuses on both hematological cancers, such as myelomas and lymphomas, and solid cancers such as oncogene addicted lung cancer,” he explains. Alessandra Fionda, Head of Medical Affairs, Oncology, Takeda Italia – our pipeline focuses on immuno-oncology, an approach that is based on the mechanisms of immuno-surveillance exercised by our immune system to counteract the presence of cancer. In fact, the ability of the cancer cell to implement sophisticated biological mechanisms to make itself unrecognizable by the immune system, eluding the body’s physiological defense systems, is known. The answer of our research is the development of innovative drugs with ‘ingenious’ mechanisms of action aimed at restoring the immune system’s ability to recognize cancer cells and to trigger biological phenomena that determine their death ”.


Takeda Italia’s Oncology Division works in collaboration with the scientific and patient community to contribute to research projects, improve access, management and information.

CopyAMP code

In Italy Takeda dedicates a particular focus to Personalized Medicine, through collaborations with the Academy, scientific institutions and technological partners and is a member of the Assobiotec working group on precision medicine and diagnostics. Takeda also supports the Cracking Cancer Forum, an annual event that brings together stakeholders from the cancer community to discuss issues, innovative therapies and best practices.

Among the activities aimed at patients, the flagship is the campaign “The sense of words – Another communication is possible”, which aims to increase attention to the psychosocial needs of cancer patients and improve the quality of relationships between people with cancer, doctors and caregivers starting from the word, the key element of the care relationship. A unique initiative in Italy that wants to favor the construction of shared meanings for the fundamental words of the treatment path.

September 14, 2022
© All rights reserved

Other articles in Science and Drugs


The article is in Italian

Tags: Takeda Italia years commitment cancer

PREV Oss: search for 350 health and social workers, also in Puglia
NEXT agricultural diesel reaches … skyrocketing, Cia Puglia asks for the intervention of the Antitrust